FOXO4-DRI Protocol: Complete Cycling & Dosing Guide
FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent cells—damaged, non-dividing cells that accumulate with age and contribute to tissue dysfunction, fibrosis, and chronic inflammation. Unlike broad immunosuppressants or cytotoxic drugs, FOXO4-DRI works by disrupting the FOXO4-p53 interaction within senescent cells specifically, allowing p53 to trigger apoptosis in these dysfunctional cells while largely sparing healthy tissue.
The peptide operates through a precise mechanism: senescent cells survive by sequestering p53 in the nucleus via FOXO4 binding. FOXO4-DRI acts as a competitive antagonist, freeing p53 to translocate to mitochondria and initiate cell death. This selectivity is why FOXO4-DRI is considered a rational senolytic—it targets the disease state rather than indiscriminately killing cells.
From a practical standpoint, FOXO4-DRI is administered via subcutaneous injection, typically in 3-week cycles repeated periodically. Dosing ranges from 1–5 mg/kg body weight, dosed 3 times per week. The protocol is straightforward to execute but requires attention to injection technique, timing, and post-injection symptom management.
Critical Note on Evidence: FOXO4-DRI has been extensively studied in animal models and isolated cell systems, demonstrating consistent senolytic activity. However, as of now, no human clinical trials have been published. All human-context data is observational or mechanistic. Use outside of supervised research settings carries substantial and undefined risk. This guide is educational and does not constitute medical advice.
The established research dosing is 1–5 mg/kg body weight. Your starting point depends on your body weight and risk tolerance:
- Lighter individuals (120–150 lbs): 100–300 mg per dose
- Average individuals (150–200 lbs): 150–450 mg per dose
- Heavier individuals (200+ lbs): 200–600 mg per dose
Most researchers begin at the lower-to-mid range (2–3 mg/kg) and assess tolerance before escalating. This translates to roughly 150–300 mg per injection for most adults.
Standard 3-Week Cycle:
- Injection frequency: 3 times per week (e.g., Monday, Wednesday, Friday)
- Duration: 3 consecutive weeks
- Total injections per cycle: 9 injections
- Rest period: 1–3 weeks between cycles before repeating
Example timing for a 3-week cycle:
- Week 1: Inject days 1, 3, 5
- Week 2: Inject days 8, 10, 12
- Week 3: Inject days 15, 17, 19
- Rest: Days 20–26 (minimum 1 week; 2–3 weeks is often preferred)
- Repeat cycle or assess before restarting
If starting at 2 mg/kg and tolerating well:
- Cycle 1: 2 mg/kg, 3x/week × 3 weeks
- 1–2 week rest
- Cycle 2: 2.5–3 mg/kg, 3x/week × 3 weeks
- 1–2 week rest
- Cycle 3+: 3–5 mg/kg as tolerated, maintaining 3x/week × 3 weeks with 1–3 week rest intervals
Do not escalate dose within a single cycle. Progress between cycles only if no adverse effects or if effects plateau.
Cycle Structure: 3-week standard protocol, repeated every 6–8 weeks (3 cycles per year)
Dosing: 2–4 mg/kg, 3x/week
Rationale: This is the evidence-supported use case. Goal is to reduce baseline senescent cell burden and associated inflammatory signaling.
Timeline:
- Cycle 1 (weeks 1–3): 2 mg/kg × 3/week
- Rest (weeks 4–5): 2 weeks
- Cycle 2 (weeks 6–8): 3 mg/kg × 3/week
- Rest (weeks 9–10): 2 weeks
- Cycle 3 (weeks 11–13): 3–4 mg/kg × 3/week
- Extended rest (weeks 14–19): 6 weeks before reassessing
Signs it's working:
- Reduced transient post-injection fatigue by cycle 2–3 (suggests senescent cell clearance stabilizing)
- Improved sleep quality or energy baseline weeks 2–3 post-cycle
- Reduction in inflammatory markers (if bloodwork monitored) 2–3 weeks after cycle completion
Cycle Structure: Extended protocol—4 weeks of injections instead of 3
Dosing: 3–5 mg/kg, 3x/week × 4 weeks
Rationale: Fibrotic tissues contain elevated senescent fibroblasts. A 4-week protocol may improve senescent cell clearance in fibrotic compartments.
Timeline:
- Week 1–4: 3 mg/kg, 3x/week (12 total injections)
- Rest: 3–4 weeks
- Repeat if needed (fibrosis protocols often use 2–3 cycles over 3–4 months)
Monitoring: Track inflammation markers and tissue-specific imaging if available (e.g., lung imaging for pulmonary fibrosis, skin for scleroderma).
Cycle Structure: 3-week standard protocol, repeated every 8 weeks
Dosing: 2.5–4 mg/kg, 3x/week
Rationale: Animal data shows FOXO4-DRI restores testosterone by clearing senescent Leydig cells. This is a secondary but promising application.
Timeline:
- Cycle 1: 2.5 mg/kg × 3/week × 3 weeks
- Rest: 2 weeks
- Cycle 2: 3–4 mg/kg × 3/week × 3 weeks
- Extended rest: 6–8 weeks before repeating
Monitoring: Testosterone and LH levels pre-cycle and 2–3 weeks post-cycle. Semen analysis if fertility is a goal (assess 8–12 weeks post-injection, as spermatogenesis takes time).
Signs it's working:
- Improved libido or sexual function weeks 2–4 post-cycle
- Improved energy and mood baseline elevation 3–4 weeks post-cycle
- Increased testicular volume or sperm parameters on follow-up analysis
Cycle Structure: 3-week standard protocol, repeated every 6–12 weeks
Dosing: 2–3.5 mg/kg, 3x/week
Rationale: FOXO4-DRI clears senescent endothelial cells, potentially improving vascular compliance and reducing atherosclerotic burden.
Timeline:
- Cycle 1: 2 mg/kg × 3/week × 3 weeks
- Rest: 2–3 weeks
- Cycle 2: 2.5–3 mg/kg × 3/week × 3 weeks
- Extended rest: 6–8 weeks
Monitoring: Consider vascular imaging (endothelial function testing, arterial stiffness measures) pre- and 4–6 weeks post-cycle.
-
Reconstitution (if lyophilized):
- Use sterile bacteriostatic water or 0.9% sodium chloride (normal saline)
- Add appropriate volume to achieve desired concentration—typically 10–50 mg/mL
- Example: 500 mg vial + 50 mL sterile water = 10 mg/mL
- Gently swirl (do not shake vigorously) for 1–2 minutes until fully dissolved
- Store reconstituted peptide at 2–8°C; use within 30 days
-
Calculate your dose:
- Body weight (lbs) ÷ 2.2 = weight in kg
- Weight (kg) × desired mg/kg dose = total mg for injection
- Example: 180 lbs = 82 kg; 82 kg × 3 mg/kg = 246 mg needed
-
Determine injection volume:
- If concentration is 10 mg/mL and you need 246 mg: 246 ÷ 10 = 24.6 mL
- If volume exceeds 1 mL, consider splitting into two injections (one per side of abdomen)
-
Site selection: Rotate between lower abdomen, upper thigh, and back of upper arm. Avoid injecting directly over muscle.
-
Sanitation:
- Clean injection site with 70% isopropyl alcohol swab
- Allow to air dry completely (30–60 seconds)
- Do not re-touch the sterile area
-
Injection:
- Use a fresh 25–29 gauge insulin syringe or tuberculin syringe
- Pinch the skin gently to elevate subcutaneous tissue
- Insert needle at 45–90° angle, half-inch depth
- Inject peptide slowly over 5–10 seconds
- Withdraw needle and apply light pressure with sterile gauze for 30 seconds
- Do not massage the site
-
Post-injection:
- Cover with small adhesive bandage if desired
- Rotate injection sites to avoid lipohypertrophy (localized fat accumulation)
12-Week Healthspan Optimization Protocol
| Week | Monday | Wednesday | Friday | Notes |
|---|
| 1 | Inject 2 mg/kg | Inject 2 mg/kg | Inject 2 mg/kg | Mild soreness, fatigue expected |
| 2 | Inject 2 mg/kg | Inject 2 mg/kg | Inject 2 mg/kg | Transient flu-like symptoms may appear |
| 3 | Inject 2 mg/kg | Inject 2 mg/kg | Inject 2 mg/kg | End of cycle—symptoms usually resolve within 3–5 days |
| 4 | REST | REST | REST | 1-week rest; monitor inflammatory markers if available |
| 5 | REST | REST | REST | 1-week rest; energy should normalize |
| 6 | Inject 3 mg/kg | Inject 3 mg/kg | Inject 3 mg/kg | Start cycle 2; dose escalation—mild increase in side effects possible |
| 7 | Inject 3 mg/kg | Inject 3 mg/kg | Inject 3 mg/kg | Effects should be milder than cycle 1 (fewer new senescent cells to clear) |
| 8 | Inject 3 mg/kg | Inject 3 mg/kg | Inject 3 mg/kg | End cycle 2 |
| 9 | REST | REST | REST | 2-week extended rest |
| 10 | REST | REST | REST | Extended rest continues |
| 11 | Inject 3.5 mg/kg | Inject 3.5 mg/kg | Inject 3.5 mg/kg | Start cycle 3; final escalation |
| 12 | Inject 3.5 mg/kg | Inject 3.5 mg/kg | Inject 3.5 mg/kg | End cycle 3; prepare for 8–12 week extended rest |
- Injection site: Localized erythema (redness), mild warmth, slight induration (firmness). Normal and self-limiting.
- Systemic: Minimal acute reaction in most people.
Day 1–3 Post-Injection
- Fatigue and malaise: Often transient, peaks 12–24 hours post-injection and resolves within 2–3 days. Related to inflammatory cytokine release from senescent cell apoptosis.
- Flu-like symptoms: Chills, mild fever (99–100.5°F), myalgia, headache. These are signs that senescent cell clearance is occurring.
- Appetite: Mild reduction is common.
Day 3–7 Post-Injection Cycle
- Inflammatory marker elevation: If bloodwork is monitored, expect transient increases in IL-6, TNF-α, CRP. These peak around day 2–4 post-injection and normalize by day 7.
- Symptom resolution: Fatigue and malaise resolve completely in most people by day 5–7.
- Energy rebound: Many report improved baseline energy 3–4 days post-injection cycle as acute inflammation resolves.
Between Cycles (1–2 weeks post-cycle completion)
- Tissue remodeling: Ongoing cellular changes as senescent cells are permanently eliminated and healthy cells repopulate.
- Improved recovery metrics: Sleep quality, baseline energy, exercise tolerance often improve 2–3 weeks after cycle completion.
- Reduced acute symptoms: Because fewer senescent cells remain, cycle 2 and subsequent cycles often produce milder fatigue and flu-like symptoms than cycle 1.
- Cumulative improvements: Chronic inflammatory markers trend lower with repeated cycles. Effects on specific health markers (testosterone, fibrosis burden, endothelial function) may take 2–3 cycles to become apparent.
Error: Increasing dose during the same 3-week cycle based on mild symptoms.
Why it's wrong: Senescent cells are being cleared progressively. Adding more peptide compounds the cytokine release and worsens symptoms without additional benefit.
Solution: Maintain consistent dose throughout a single cycle. Escalate only between cycles if well-tolerated.
Error: Starting a new cycle within 3–5 days of the previous cycle's completion.
Why it's wrong: Inflammatory resolution is still occurring. Restarting before this stabilizes amplifies fatigue and systemic symptoms.
Solution: Maintain minimum 1-week (preferably 2-week) rest between cycles.
Error: Assuming higher doses = faster results; jumping to 5 mg/kg on the first cycle.
Why it's wrong: Higher doses increase off-target apoptosis risk and dramatically amplify SASP-related symptoms without evidence of better outcomes.
Solution: Start at 2–2.5 mg/kg. Escalate gradually (0.5–1 mg/kg increments) between cycles over 2–3 cycles.
Error: Reusing needles, injecting into muscle, massaging injection sites heavily, or failing to rotate sites.
Why it's wrong: Reused needles cause infection risk and increased local inflammation. Muscle injection causes pain and potential off-target effects. Poor rotation causes lipohypertrophy, which impairs absorption.
Solution: Use fresh needles every time. Inject subcutaneously (not into muscle). Rotate sites systematically. Apply light pressure without massage.
Error: Ignoring persistent or worsening side effects; continuing to inject despite concerning signs.
Why it's wrong: Sustained elevation in side effects may indicate inadequate rest, infection, or an adverse reaction requiring protocol adjustment or medical attention.
Solution: Track post-injection symptoms in a simple log. If fatigue persists beyond 7 days or fever exceeds 101°F, pause and consult a physician.
FOXO4-DRI functions as a senolytic foundation. Its mechanism is distinct from growth factors, hormonal agents, or anti-inflammatory compounds, enabling rational stacking.
Rationale: FOXO4-DRI clears senescent Leydig cells; TRT replaces lost hormone signaling. Combined, they address senescent cell-mediated dysfunction and hormone deficit.
**Protocol